Farmland Partners (FPI) Company Overview

Land has proven to be an excellent long-term risk-adjusted investment. Fortunately, there are numerous opportunities to buy it at a steep discount right now. I share three compelling opportunities, yielding up to 7.3% with big buybacks involved as well.

Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Nov. 11, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof.

Farmland Partners, Inc. (NYSE:FPI ) Q3 2024 Earnings Conference Call October 31, 2024 11:00 AM ET Company Participants Christine Garrison - General Counsel Luca Fabbri - President and CEO Paul Pittman - Executive Chairman Susan Landi - Chief Financial Officer Conference Call Participants Robert Stevenson - Janney Scott Fortune - ROTH Capital Partners Buck Horne - Raymond James John Massocca - B. Riley Craig Kucera - Lucid Capital Markets Operator Thank you for standing by.

Farmland Partners (FPI) came out with quarterly funds from operations (FFO) of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.01 per share a year ago.

A very defensive sector that has bright long-term prospects has seen stock prices languish recently. We look at two opportunities that offer attractive dividends and trade at compelling valuations. We discuss why we want to buy the dip.

Farmland Partners (FPI) came out with quarterly funds from operations (FFO) of $0.01 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.02 per share a year ago.

Investing in Real Estate Investment Trusts (REITs) is great if you're in search of dividends. Moreover, numerous REITs have shed value since the turn of the year, suggesting a buying opportunity has emerged.

Farmland Partners (FPI) was a big mover last session on higher-than-average trading volume. The latest trend in FFO estimate revisions might not help the stock continue moving higher in the near term.

Farmland Partners (FPI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.